Finazzi G, Barbui T
Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy.
Thromb Haemost. 1994 Jan;71(1):15-8.
A cohort study was undertaken to compare the incidence of thrombosis in patients with inherited deficiency of Antithrombin III (n = 9), Protein C (n = 36) and Protein S (n = 36). The patients were stratified for schedule of antithrombotic prophylaxis and followed for a total period of 160 patient-years. Seven venous thrombosis were observed for a total incidence of 4.3% pts.-ys. The incidence of thrombosis was not significantly different in patients of different age, sex and schedule of prophylaxis, although there was a trend to a lower incidence in young individuals and in those receiving long-term oral anticoagulation. Patients with AT III deficiency had an higher incidence of thrombosis than patients with Protein C or Protein S deficiency (12 vs. 2.8 vs. 3.3% pts.-ys, p < 0.05), despite the fact that they were, on average, younger and more prophylaxed. This study suggests that congenital Antithrombin III deficiency constitutes a greater risk of thrombosis than congenital deficiencies of Protein C and Protein S.
开展了一项队列研究，以比较抗凝血酶III遗传性缺乏症患者（n = 9）、蛋白C缺乏症患者（n = 36）和蛋白S缺乏症患者（n = 36）的血栓形成发生率。根据抗血栓预防方案对患者进行分层，并随访了总计160患者年。观察到7例静脉血栓形成，总发生率为4.3%患者年。不同年龄、性别和预防方案的患者血栓形成发生率无显著差异，尽管年轻个体和接受长期口服抗凝治疗的患者血栓形成发生率有降低趋势。尽管抗凝血酶III缺乏症患者平均年龄更小且预防措施更多，但与蛋白C或蛋白S缺乏症患者相比，其血栓形成发生率更高（分别为12%患者年、2.8%患者年和3.3%患者年，p < 0.05）。这项研究表明，先天性抗凝血酶III缺乏症比先天性蛋白C和蛋白S缺乏症构成更大的血栓形成风险。
